Work

Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.

Year: 2010

Type: article

Source: PubMed

Author: Ruben A Mesa

Institutions: Mayo Clinic, Mayo Clinic in Arizona

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1417342202

FWCI: 3.118

Cites:

Cited by: 104

Related to: 10